Rokos Hedge Fund Places Billions on Tech Stocks (The Star)
Rokos Capital Management bought more than US$2.7bil of shares in the Invesco QQQ Trust in the last quarter, part of a wager on the technology sector. The firm, led by billionaire Chris Rokos, held 7.67 million shares of the exchange-traded fund (ETF) at midyear, up from 232,382 at the end of March, according to a regulatory filing on Monday. Rokos, which specialises in macroeconomic bets, also purchased put options on 7.5 million QQQ shares, along with call options on 1.9 million shares.
Ex-Bridgewater Exec Bob Elliott Plans to Launch Eight Hedge Fund ETFs (Financial News)
The firm raised venture capital earlier this year to help expand its lineup. Bob Elliott’s Unlimited Funds, an investment firm he started last year, is aiming to offer eight new exchange traded funds, according to a filing with the US Securities and Exchange Commission. The firm, which seeks to create ETFs that provide access to returns replicated from alternative strategies within the hedge fund industry and beyond, raised venture capital earlier this year to help expand its lineup.
A Top Two Sigma Investment Executive has Taken Leave from the Firm Amid a Series of Challenges for the Hedge Fund Giant (Business Insider)
A senior Two Sigma investment executive has taken a leave of absence from the firm, Insider has learned. Alex Ginsburg, a 21-year company veteran and chief investment officer for equities research, has stepped away from his role at the hedge fund to take a medical leave, according to people familiar with the matter. The company notified investors of the executive’s departure and announced it internally in mid-July, along with other personnel changes including the appointment of Jeff Penney and Timothy Reynolds as interim co-chief operating officers, according to people familiar with the matter.
Thursday 8/17 Insider Buying Report: PGEN, TSHA (Nasdaq.com)
On Wednesday, Precigen’s Randal J. Kirk, made a $757,612 purchase of PGEN, buying 500,000 shares at a cost of $1.52 each. Kirk was up about 9.5% on the buy at the high point of today’s trading session, with PGEN trading as high as $1.66 in trading on Thursday. Precigen is trading up about 8.1% on the day Thursday. And also on Wednesday, Director John A. Stalfort III bought $700,000 worth of Taysha Gene Therapies, buying 777,778 shares at a cost of $0.90 a piece. This buy marks the first one filed by Stalfort III in the past twelve months. Taysha Gene Therapies is trading up about 4.1% on the day Thursday. Stalfort III was up about 153.3% on the purchase at the high point of today’s trading session, with TSHA trading as high as $2.28 in trading on Thursday.
Over $25M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying (Benzinga)
Sigilon Therapeutics: The Trade: Sigilon Therapeutics, Inc. (SGTX) 10% owner Shenandoah Acquisition Corp bought a total of 1,718,493 shares at an average price of $14.92. To acquire these shares, it cost around $25.64 million. Sarepta Therapeutics: The Trade: Sarepta Therapeutics, Inc. (SRPT) Director Michael Chambers acquired a total of 23,686 shares at an average price of $108.05. To acquire these shares, it cost around $2.56 million.
